Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients
Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients
Catalyst Events Expected in Q2 2024 for Two Randomized.
/PRNewswire/ Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA).
MENLO PARK, Calif., January 03, 2024 Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 09, 2024, at 1:30 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executive Officer and President, will provide details around the progress of our organization, including updates related to the development of our i
/PRNewswire/ Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in.
The frontline combination of cadonilimab and platinum-based chemotherapy with or without bevacizumab provided a progression-free survival benefit in patients with recurrent or metastatic cervical cancer.